Dr. Kevin Simon Shares Insights in Implicit Bias and Cultural Stigma

Rhea-AI Summary

Alkermes hosted an enlightening discussion featuring Dr. Kevin M. Simon, Boston's Chief Behavioral Health Officer, addressing implicit bias and mental health stigma in minority communities. Dr. Simon highlighted the mental health challenges faced by Dr. Martin Luther King Jr. and emphasized the importance of allyship in promoting diversity and inclusion. Alkermes continues to focus on ending the stigma surrounding mental health issues, aligning with its commitment to innovation in neuroscience and oncology.

With a global presence, Alkermes develops medicines for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, alongside an evolving pipeline for neurodegenerative disorders and cancer.

Positive

• Engagement with community leaders like Dr. Simon highlights Alkermes' commitment to diversity and inclusion.
• Focus on mental health aligns with current societal demands, potentially enhancing public perception.

Negative

• None.

NORTHAMPTON, MA / ACCESSWIRE / March 20, 2023 / Alkermes

Last month, Alkermes' Mosaic employee resource group hosted a conversation with Dr. Kevin M. Simon, a double-board certified psychiatrist who specializes in mental health and addiction. Dr. Simon serves as the City of Boston's first-ever Chief Behavioral Health Officer and is an attending psychiatrist at Boston Children's Hospital, as well as a current instructor of psychiatry at Harvard Medical School and a Commonwealth Fund Fellow in Health Policy at Harvard University.

Dr. Simon shared insights related to implicit bias and cultural stigma surrounding mental health in minority communities, how allies can support efforts related to diversity, inclusion and belonging and discussed the less-publicized mental health challenges that Dr. Martin Luther King Jr. faced throughout his life.

We thank Dr. Simon for this timely and important discussion as we continue to work to help end the persistent stigma surrounding mental health.

About Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com.

Contact Info:
Spokesperson: Alkermes
Website: https://www.3blmedia.com/profiles/alkermes
Email: info@3blmedia.com

SOURCE: Alkermes

View source version on accesswire.com:
https://www.accesswire.com/744711/Dr-Kevin-Simon-Shares-Insights-in-Implicit-Bias-and-Cultural-Stigma

FAQ

What insights did Dr. Kevin Simon share during the Alkermes event?

Dr. Kevin Simon discussed implicit bias, cultural stigma surrounding mental health, and the challenges faced by Dr. Martin Luther King Jr.

How does Alkermes contribute to mental health awareness?

Alkermes is actively engaged in discussions about mental health stigma through events featuring experts like Dr. Simon.

What is Alkermes' focus in the biopharmaceutical industry?

Alkermes develops innovative medicines for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, along with products targeting neurodegenerative disorders and cancer.